User Experiences of Development of Dependence on the Synthetic Cannabinoids, 5f-AKB48 and 5F-PB-22, and Subsequent Withdrawal Syndromes



Emergence of synthetic cannabinoids (SCBs) in herbal smoking mixtures is a public health concern. New SCB’s such as 5f-AKB48 and 5F-PB-22 have been detected in French seizures and in sudden death post mortems in the US. The aim was to describe development of dependence on herbal smoking mixtures containing the SCB’s, 5f-AKB48 and 5F-PB-22 and subsequent withdrawal syndromes. Dependent users of herbal smoking mixtures known to contain the SCB’s 5f-AKB48 and 5F-PB-22 with an average Severity of Dependence Score (SDS) of 13 were interviewed using a structured guide (three males/three females). Narratives were analysed using the Empirical Phenomenological Psychological (EPP) five step method. Six themes with 68 categories emerged from the analysis. Themes are illustrated as 1) Networks and Product Availability; 2) Drivers and Motives for Use; 3) Effect and Pathways toward Dependence; 4) Poly Substance Use and Comparisons to Natural Cannabis; 5) Dependence and Withdrawal and 6) Self-detoxification Attempts. Two higher levels of abstraction above these theme-levels emerged from the data, with sole use of herbal smoking mixtures containing 5f-AKB48 and 5F-PB-22 centering on the interplay between intense cravings, compulsive all-consuming seeking, use and re-dose behaviours, and fear of the psychiatric and self-harms caused when in withdrawal. This is the first study describing dependence and withdrawal experiences in users dependent on 5f-AKB48 and 5F-PB-22. Given the potential for adverse psychiatric and physical consequences of dependent use, further development of specific clinical responses and clinical research around toxicity and withdrawal severity are warranted.


Synthetic cannabinoid 5f-AKB48 5F-PB-22 Herbal cannabis, Spice, withdrawal 



This work was supported by the Health Service Executive, and Teach na nDaoine, Ireland. The opinions expressed in this article are of the researchers and are not necessarily those of the funders.

Compliance with Ethical Standards

Conflict of Interest

Authors declare no conflict of interest.


  1. Arfken, C. L., Owens, D., Madeja, C., & DeAngelis, C. (2014). Exploratory comparative study on the diffusion of synthetic cannabinoids and synthetic cathiones. Journal of Psychoactive Drugs, 46, 362–368. doi: 10.1080/02791072.2014.959214.CrossRefPubMedGoogle Scholar
  2. Auwärter, V., Dresen, S., Weinmann, W., Müller, M., Pütz, M., & Ferreirós, N. (2009). ‘spice’ and other herbal blends: harmless incense or cannabinoid designer drugs? Journal of Mass Spectrometry, 44, 832–837. doi: 10.1002/jms. 1558.CrossRefPubMedGoogle Scholar
  3. Banerji S, Deutsch CM, Bronstein AC (2010) SPICE Ain’t So Nice. Poster Final 2010.pdf Accessed May 22nd 2015.
  4. Barratt, M. J., Cakic, V., & Lenton, S. (2013). Patterns of synthetic cannabinoid use in Australia. Drug and Alcohol Review, 32, 141–146. doi: 10.1111/j.1465-3362.2012.00519.x.CrossRefPubMedGoogle Scholar
  5. Baumann, M. H., Solis Jr., E., Watterson, L. R., Marusich, J. A., Fantegrossi, W. E., & Wiley, J. L. (2014). Baths salts, spice, and related designer drugs: the science behind the headlines. The Journal of Neuroscience, 34, 15150–15158. doi: 10.1523/JNEUROSCI.3223-14.2014.CrossRefPubMedPubMedCentralGoogle Scholar
  6. Bebarta, V. S., Ramirez, S., & Varney, S. V. (2012). Spice: A new “legal” herbal mixture abused by young active duty military personnel. Substance Abuse, 33, 191–194. doi: 10.1080/08897077.2011.637610.CrossRefPubMedGoogle Scholar
  7. Behonick, G., Shanks, K. G., Firchau, D. J., Mathur, G., Lynch, C. F., Nashelsky, M., Jaskierny, D. J., & Meroueh, C. (2014). Four postmortem case reports with quantitative detection of the synthetic cannabinoid, 5FPB22. Journal of Analytical Toxicology, 38, 559–562. doi: 10.1093/jat/bku048.CrossRefPubMedPubMedCentralGoogle Scholar
  8. Berry-Caban, C. S., Ee, J., Ingram, V., Berry, C. E., & Kim, E. H. (2013). Synthetic cannabinoid overdose in a 20-year-old Male US soldier. Substance Abuse, 34, 70–72. doi: 10.1080/08897077.2012.677754.CrossRefPubMedGoogle Scholar
  9. Brents, L. K., & Prather, P. L. (2014). The K2/spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products. Drug Metabolism Reviews, 46, 72–85. doi: 10.3109/03602532.2013.839700.CrossRefPubMedGoogle Scholar
  10. Brents, L. K., Reichard, E. E., Zimmerman, S. M., Moran, J. H., Fantegrossi, W. E., & Prather, P. L. (2011). Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PloS One, 6, e21917. doi: 10.1371/journal.pone.0021917.CrossRefPubMedPubMedCentralGoogle Scholar
  11. Brents, L. K., Gallus-Zawada, A., Radominska-Pandya, A., Vasilievik, T., Prisinzano, T. E., Fantegrossi, W. E., Moran, J. H., & Prather, P. L. (2012). Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochemical Pharmacology, 83, 952–961. doi: 10.1016/j.bcp.2012.01.004.CrossRefPubMedPubMedCentralGoogle Scholar
  12. Bright, S. J., Bishop, B., Kane, R., Marsh, A., & Barratt, M. J. (2013). Kronic hysteria: exploring the intersection between Australian synthetic cannabis legislation, the media, and drug-related harm. The International Journal on Drug Policy, 24, 231–237. doi: 10.1016/j.drugpo.2012.12.002.CrossRefPubMedGoogle Scholar
  13. Bryner J (2010) Fake weed, real drug: K2 causing hallucinations in teens. In: Live Science. Available via DIALOG. . Accessed March 16th 2010.
  14. Budney, A. J., & Stanger, C. (2012). Cannabis use and misuse. In J. M. Rey (Ed.), IACAPAP e-textbook of child and adolescent mental health (p. G2). Geneva: International Association for Child and Adolescent Psychiatry and Allied Profession.Google Scholar
  15. Castellanos, D., Singh, S., Thornton, G., Avila, M., & Moreno, A. (2011). Synthetic cannabinoid use: A case series of adolescents. The Journal of Adolescent Health, 49, 347–349. doi: 10.1016/j.jadohealth.2011.08.002.CrossRefPubMedGoogle Scholar
  16. Caviness, C. M., Tzilos, G., Anderson, B. J., & Stein, M. D. (2015). Synthetic cannabinoids: use and predictors in a community sample of young adults. Substance Abuse, 36, 368–373. doi: 10.1080/08897077.2014.9591.CrossRefPubMedGoogle Scholar
  17. Chung, T., Martin, C. S., Cornelius, J. R., & Clark, D. B. (2008). Cannabis withdrawal predicts severity of cannabis involvement at 1-year follow-up among treated adolescents. Addiction, 103, 787–799. doi: 10.1111/j.1360-0443.2008.02158.x.CrossRefPubMedPubMedCentralGoogle Scholar
  18. Coffey, C., Carlin, J. B., Degenhardt, L., Lynskey, M., Sanci, L., & Patton, G. C. (2002). Cannabis dependence in young adults: an Australian population study. Addiction, 97, 187–194.CrossRefPubMedGoogle Scholar
  19. Copersino, M. L., Boyd, S. J., Tashkin, D. P., Huestis, M. A., Heishman, S. J., Dermand, J. C., Simmons, M. S., & Gorelick, D. A. (2006). Cannabis withdrawal among non-treatment-seeking adult cannabis users. The American Journal on Addictions, 15, 8–14.CrossRefPubMedGoogle Scholar
  20. Cornelius, J. R., Chung, T., Martin, C., Wood, D. S., & Clark, D. B. (2008). Cannabis withdrawal is common among treatment-seeking adolescents with cannabis dependence and major depression, and is associated with rapid relapse to dependence. Addictive Behaviors, 33, 1500–1505. doi: 10.1016/j.addbeh.2008.02.001.CrossRefPubMedPubMedCentralGoogle Scholar
  21. Dargan, P. I., Hudson, S., Ramsey, J., & Wood, D. M. (2011). The impact of changes in UK classification of the synthetic cannabinoid receptor agonists in ‘spice’. The International Journal on Drug Policy, 22, 274–277. doi: 10.1016/j.drugpo.2011.02.006.CrossRefPubMedGoogle Scholar
  22. Deluca, P., Schifano, F., Davey, Z., Corazza, O., di Furia, L., Farre, M., Flesland, L., Mannonen, M., Majava, A., Valentina, M., Pagani, S., Peltoniemi, T., Scherbaum, N., Siemann, H., Skutle, A., Torrens, M., Pezzolesi, C., & van der Kreeft, P. (2009). Spice report Psychonaut Web Mapping Research Project. King’s College London: The Psychonaut Web Mapping Research Group.Google Scholar
  23. Dresen, S., Kneisel, S., Weinmann, W., Zimmermann, R., & Auwarter, V. (2011). Development and validation of a liquid chromatography-tandem mass spectrometry method for the quantitation of synthetic cannabinoids of the aminoalkylindole type and methanandamide in serum and its application to forensic samples. Journal of Mass Spectrometry, 46, 163–171. doi: 10.1002/jms.1877.CrossRefPubMedGoogle Scholar
  24. Egan, K. L., Suerken, C. K., Reboussin, B. A., Spangler, J., Wagoner, K. G., Sutfin, E. L., Debinski, B., & Wolfson, M. (2015). K2 and spice use among a cohort of college students in southeast region of the USA. The Am J Drug Alcohol Abuse, 41, 317–322. doi: 10.3109/00952990.2015.1043438.CrossRefPubMedGoogle Scholar
  25. European Monitoring Centre for Drugs and Drug Addiction – EMCDDA (2009) Thematic paper - Understanding the ‘spice’ phenomenon. Office for Official Publications of the European Communities, Luxembourg. Available via DIALOG. Accessed 28th July 2013.
  26. Ernst, L., Schiebel, H. M., Theuring, C., Lindigkeit, R., & Beuerle, T. (2011). Identification and characterization of JWH-122 used as new ingredient in “spice-like” herbal incenses. Forensic Science International, 208, e31–e35. doi: 10.1016/j.forsciint.2011.03.020.CrossRefPubMedGoogle Scholar
  27. Every-Palmer, S. (2010). Warning: legal synthetic cannabinoid-receptor agonists such as JWH-018 may precipitate psychosis in vulnerable individuals. Addiction, 105, 1859–1860. doi: 10.1111/j.1360-0443.2010.03119.x.CrossRefPubMedGoogle Scholar
  28. Every-Palmer, S. (2011). Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug and Alcohol Dependence, 117, 152–157. doi: 10.1016/j.drugalcdep.2011.01.012.CrossRefPubMedGoogle Scholar
  29. Fantegrossi, W. E., Moran, J. H., Radominska-Pandya, A., & Prather, P. L. (2014). Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ9-THC: mechanism underlying greater toxicity? Life Sciences, 97, 45–54. doi: 10.1016/j.lfs.2013.09.017.CrossRefPubMedGoogle Scholar
  30. Fattore, L., & Fratta, W. (2011). Beyond THC: the new generation of cannabinoid designer drugs. Frontiers in Behavioral Neuroscience, 5, 60. doi: 10.3389/fnbeh.2011.00060.CrossRefPubMedPubMedCentralGoogle Scholar
  31. Forrester, M. B., Kleinschmidt, K., Schwarz, E., & Young, A. (2011). Synthetic cannabinoid exposures reported to Texas poison centers. Journal of Addictive Diseases, 30, 351–358. doi: 10.1080/10550887.2011.609807.CrossRefPubMedGoogle Scholar
  32. Gillespie, N. A., Neale, M. C., Prescott, C. A., Aggen, S. H., & Kendler, K. S. (2007). Addiction, 10, 920–930.CrossRefGoogle Scholar
  33. Gossop, M., Darke, S., Griffiths, P., Hando, J., Powis, B., Hall, W., & Strang, J. (1995). The severity of dependence scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction, 90, 607–614.CrossRefPubMedGoogle Scholar
  34. Griffiths, P., Sedefov, R., Gallegos, A., & Lopez, D. (2010). How globalization and market innovation challenge how we think about and respond to drug use: ‘spice’ a case study. Addiction, 105, 951–953. doi: 10.1111/j.1360-0443.2009.02874.x.CrossRefPubMedGoogle Scholar
  35. Grigoryev, A., Melnik, A., Savchuk, S., Simonov, A., & Rozhanets, V. (2011a). Gas and liquid chromatography-mass spectrometry studies on the metabolism of the synthetic phenylacetylindole cannabimimetic JWH-250, the psychoactive component of smoking mixtures. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 879, 2519–2526. doi: 10.1016/j.jchromb.2011.07.004.CrossRefPubMedGoogle Scholar
  36. Grigoryev, A., Savchuk, S., Melnik, A., Moskaleva, N., Dzhurko, J., Ershov, M., Nosyrev, A., Vedenin, A., Izotov, B., Zabirova, I., & Rozhanets, V. (2011b). Chromatography-mass spectrometry studies on the metabolism of synthetic cannabinoids JWH-018 and JWH-073, psychoactive components of smoking mixtures. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 879, 1126–1136. doi: 10.1016/j.jchromb.2011.03.034.CrossRefPubMedGoogle Scholar
  37. Gunderson, E. W., Haughey, H. M., Ait-Daoud, N., Joshi, A. S., & Hart, C. L. (2012). “spice” and “K2” herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. The American Journal on Addictions, 21, 320–326. doi: 10.1111/j.1521-0391.2012.00240.x.CrossRefPubMedGoogle Scholar
  38. Gunderson, E. W., Haughey, H. M., Ait-Daoud, N., Joshi, A. S., & Hart, C. L. (2014). A survey of synthetic cannabinoid consumption by current cannabis users. Substance Abuse, 35, 184–189. doi: 10.1080/08897077.2013.846288.CrossRefPubMedPubMedCentralGoogle Scholar
  39. Helander, A., Beck, O., Hägerkvist, R., & Hulthén, P. (2013). Identification of novel psychoactive drug use in Sweden based on laboratory analysis: initial experiences from the STRIDA project. Scandinavian Journal of Clinical and Laboratory Investigation, 73, 400–406. doi: 10.3109/00365513.2013.793817.CrossRefPubMedGoogle Scholar
  40. Hermanns-Clausen, M., Kneisel, S., Szabo, B., & Auwarter, V. (2013). Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction, 108, 534–544. doi: 10.1111/j.1360-0443.2012.04078.x.CrossRefPubMedGoogle Scholar
  41. Hillebrand, J., Olszewski, D., & Sedefov, R. (2010). Legal highs on the internet. Substance Use & Misuse, 45, 330–340. doi: 10.3109/10826080903443628.CrossRefGoogle Scholar
  42. Hudson, S., Ramsey, J., King, L., Timbers, S., Maynard, S., Dargan, P. I., & Wood, D. M. (2010). Use of high-resolution accurate mass spectrometry to detect reported and previously unreported cannabinomimetics in “herbal high” products. Journal of Analytical Toxicology, 34, 252–260.CrossRefPubMedGoogle Scholar
  43. Hurst, D., Loeffler, G., & McLay, R. (2011). Psychosis associated with synthetic cannabinoid agonists: a case series. The American Journal of Psychiatry, 168, 1119. doi: 10.1176/appi.ajp.2011.11010176.CrossRefPubMedGoogle Scholar
  44. Husserl, E. (1970). Logical investigation. New York: Humanities Press.Google Scholar
  45. Johnston, L. D., O’Malley, P. M., Miech, R. A., Bachman, J. G., & JE, S. (2015). Monitoring the Future national survey results on drug use: 1975-2014: Overview, key findings on adolescent drug use. Institute For Social Research. Ann Arbor, MI: The University of Michigan.Google Scholar
  46. Karlsson, G. (1995). Psychological qualitative research from a phenomenological perspective. Stockholm, Sweden: Almqvist & Wiksell International.Google Scholar
  47. Kavanagh P, Spiers P, O’Brien J, McNamara S, Angelov D, Mullan D, Talbot B, Ryder S (2010) Head shop ‘legal highs’ active constituents identification chart (July/August 2010, ‘714’ – ‘823’). Department of Pharmacology and Therapeutics, TCD, Dublin. Available via Accessed 20th July 2015.
  48. Kikura-Hanajiri, R., Uchiyama, N., & Goda, Y. (2011). Survey of current trends in the abuse of psychotropic substances and plants in Japan. Leg Med (Tokyo), 13, 109–115. doi: 10.1016/j.legalmed.2011.02.003.CrossRefGoogle Scholar
  49. Kjellgren, A., & Jonsson, K. (2013). Methoxetamine (MXE)–a phenomenological study of experiences induced by a “legal high” from the internet. Journal of Psychoactive Drugs, 45, 276–286.CrossRefPubMedPubMedCentralGoogle Scholar
  50. Levasseur, J. J. (2003). The problem of bracketing in phenomenology. Qualitative Health Research, 13, 408–420. doi: 10.1177/1049732302250337.CrossRefPubMedGoogle Scholar
  51. Lincoln, Y. S., & Guba, E. G. (1985). Naturalistic inquiry. Beverly Hills, CA: Sage.Google Scholar
  52. Lindigkeit, R., Boehme, A., Eiserloh, I., Luebbecke, M., Wiggermann, M., Ernst, L., & Beuerle, T. (2009). Spice: A never ending story? Forensic Science International, 191, 58–63. doi: 10.1016/j.forsciint.2009.06.008.CrossRefPubMedGoogle Scholar
  53. McElrath, K., & Van Hout, M. C. (2011). A preference for mephedrone: Drug Markets, drugs of choice and the emerging ‘legal high’ scene. Journal of Drug Issues, 41, 487–507.CrossRefGoogle Scholar
  54. Meshack A, Peters RJ.Jr, Mi-Ting L, Hill M, Abughosh S, Essien EJ, Savage C (2013) The beliefs of teenage male cannabinoid users: a qualitative study. American Journal of Health Studies 28:109–113.Google Scholar
  55. Müller, H., Huttner, H. B., Kohrmann, M., Wielopolski, J. E., Kornhuber, J., & Sperling, W. (2010a). Panic attack after spice abuse in a patient with ADHD. Pharmacopsychiatry, 43, 152–153. doi: 10.1055/s-0029-1243252.CrossRefPubMedGoogle Scholar
  56. Müller, H., Sperling, W., Kohrmann, M., Huttner, H. B., Kornhuber, J., & Maler, J. M. (2010b). The synthetic cannabinoid spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophrenia Research, 118, 309–310. doi: 10.1016/j.schres.2009.12.001.CrossRefPubMedGoogle Scholar
  57. Pierre, J. M. (2011). Cannabis, synthetic cannabinoids, and psychosis risk: what the evidence says: research suggests marijuana may be a ‘component cause’ of psychosis. Current Psychology, 10, 9.Google Scholar
  58. Rominger, A., Cumming, P., Xiong, G., Koller, G., Forster, S., Zwergal, A., Karamatskos, E., Bartenstein, P., La Fougere, C., & Pogarell, O. (2013). Effects of acute detoxification of the herbal blend ‘spice gold’ on dopamine D2/3 receptor availability: a [18F]fallypride PET study. European Neuropsychopharmacology, 23, 1606–1610. doi: 10.1016/j.euroneuro.2013.01.009.CrossRefPubMedGoogle Scholar
  59. Roussel, O., Carlin, M. G., Bouvot, X., & Tensorer, L. (2015). The emergence of synthetic cannabinoids in Mayotte. Toxicologie Analytique et Clinique, 27, 18–22. doi: 10.1016/j.toxac.2014.12.002.CrossRefGoogle Scholar
  60. Schifano, F., Deluca, P., Baldacchino, A., Peltoniemi, T., Scherbaum, N., Torrens, M., Farre, M., Flores, I., Rossi, M., Eastwood, D., Guionnet, C., Rawaf, S., Agosti, L., Di Furia, L., Brigada, R., Majava, A., Siemann, H., Leoni, M., Tomasin, A., Rovetto, F., & Ghodse, A. H. (2006). Drugs on the web; the Psychonaut 2002 EU project. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 30, 640–646.CrossRefGoogle Scholar
  61. Schifano, F., Corazza, O., Deluca, P., Davey, Z., Lucia, D. F., Farre, M., Flesland, L., Mannonen, M., Pagani, S., Peltoniemi, T., Pezzolesi, C., Scherbaum, N., Siemann, H., Skutle, A., Torrens, M., & Van Der Kreeft, P. (2009). Psychoactive drug mystical incense? overview of the online available information on spice products. Int J Cult Ment Health, 2, 137–144. doi: 10.1080/17542860903350888.CrossRefGoogle Scholar
  62. Schifano, F., Ricciardi, A., Corazza, O., Deluca, P., Davey, Z., & Rafanelli, C. (2010). New drugs of abuse on the Web: the role of the Psychonaut Web Mapping Project. Rivista di Psichiatria, 45, 88–93.PubMedGoogle Scholar
  63. Schneir, A. B., Cullen, J., & Ly, B. T. (2011). “spice” girls: synthetic cannabinoid intoxication. The Journal of Emergency Medicine, 40, 296–269. doi: 10.1016/j.jemermed.2010.10.014.CrossRefPubMedGoogle Scholar
  64. Seely, K. A., Prather, P. L., James, L. P., & Moran, J. H. (2011). Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Molecular Interventions, 11, 36–51. doi: 10.1124/mi.11.1.6.CrossRefPubMedPubMedCentralGoogle Scholar
  65. Seely, K. A., Lapoint, J., Moran, J. H., & Frattore, L. (2012). Spice drugs are more than harmless herbal blends: A review of the pharmacology and toxicology of synthetic cannabinoids. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 39, 234–243. doi: 10.1016/j.pnpbp.2012.04.017.CrossRefGoogle Scholar
  66. Simmons, J. R., Skinner, C. G., Williams, J., Kang, C. S., Schwartz, M. D., & Wills, B. K. (2011a). Intoxication from smoking “spice”. Annals of Emergency Medicine, 57, 187–188. doi: 10.1016/j.annemergmed.2010.08.039.CrossRefPubMedGoogle Scholar
  67. Simmons, J., Cookman, L., Kang, C., & Skinner, C. (2011b). Three cases of “spice” exposure. Clinical Toxicology (Philadelphia, Pa.), 49, 431–433. doi: 10.3109/15563650.2011.584316.CrossRefGoogle Scholar
  68. Sobolevsky, T., Prasolov, I., & Rodchenkov, G. (2010). Detection of JWH-018 metabolites in smoking mixture post-administration urine. Forensic Science International, 200, 141–147. doi: 10.1016/j.forsciint.2010.04.003.CrossRefPubMedGoogle Scholar
  69. Soussan, C., & Kjellgren, A. (2014). The flip side of “spice”: the adverse effects of synthetic cannabinoids as discussed on a Swedish internet forum. Nordic Studies on Alcohol and Drugs, 31, 207–220.CrossRefGoogle Scholar
  70. Spaderna, M., Addy, P. H., & D’Souza, D. C. (2013). Spicing things up: synthetic cannabinoids. Psychopharmacology, 228, 525–540. doi: 10.1007/s00213-013-3188-4.CrossRefPubMedPubMedCentralGoogle Scholar
  71. Tung, C. K., Chiang, T. P., & Lam, M. (2012). Acute mental disturbance caused by synthetic cannabinoid: a potential emerging substance of abuse in Hong Kong. East Asian Arch Psychiatry, 22, 31–33.PubMedGoogle Scholar
  72. Tuv, S. S., Strand, M. C., Karinen, R., Øiestad, E. L., Christophersen, A. S., & Vindenes, V. (2012). Effect and occurrence of synthetic cannabinoids. Tidsskrift for den Norske Lægeforening, 132, 2285–2288. doi: 10.4045/tidsskr.12.0471.CrossRefPubMedGoogle Scholar
  73. Uchiyama, N., Kikura-Hanajiri, R., Ogata, J., & Goda, Y. (2010). Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Science International, 198, 31–38. doi: 10.1016/j.forsciint.2010.01.004.CrossRefPubMedGoogle Scholar
  74. Van der Veer, N., & Fiday, J. (2011). Persistent psychosis following the use of spice. Schizophrenia Research, 130, 285–286. doi: 10.1016/j.schres.2011.04.022.CrossRefPubMedGoogle Scholar
  75. Van Hout, M. C., & Bingham, T. (2012). A costly turn On: patterns of use and perceived consequences of mephedrone based head shop products amongst Irish injectors. The International Journal on Drug Policy, 23, 188–197. doi: 10.1016/j.drugpo.2012.01.008.CrossRefPubMedGoogle Scholar
  76. Van Hout, M. C., & Brennan, R. (2011a). Plantfood for thought: A qualitative study of mephedrone use in Ireland. Drugs: Educ Prev Polic, 18, 371–381. doi: 10.3109/09687637.2010.537713.Google Scholar
  77. Van Hout, M. C., & Brennan, R. (2011b). Bump and grind: An exploratory study of mephedrone users’ perceptions of sexuality and sexual risk. Drug Alcohol Today, 11, 93–104.CrossRefGoogle Scholar
  78. Van Hout, M. C., & Brennan, R. (2011c). Heads held high: An exploratory study of legal highs in pre legislation Ireland. Journal of Ethnicity in Substance Abuse, 10, 256–272. doi: 10.1080/15332640.2011.600210.CrossRefPubMedGoogle Scholar
  79. Van Hout, M. C., & Brennan, R. (2012). Curiosity killed M-cat: A post legislative study on mephedrone use in Ireland. Drugs: Educ Prev Polic, 19, 156–162.Google Scholar
  80. Vandrey, R., Dunn, K. E., Fry, J. A., & Girling, E. R. (2012). A survey study to characterize use of spice products (synthetic cannabinoids). Drug and Alcohol Dependence, 120, 238–241. doi: 10.1016/j.drugalcdep.2011.07.011.CrossRefPubMedGoogle Scholar
  81. Vardakou, I., Pistos, C., & Spiliopoulou, C. H. (2010). Spice drugs as a new trend: mode of action, identification and legislation. Toxicology Letters, 197, 157–162. doi: 10.1016/j.toxlet.2010.06.002.CrossRefPubMedGoogle Scholar
  82. Vearrier, D., & Osterhoudt, K. C. (2010). A teenager with agitation: higher than she should have climbed. Pediatric Emergency Care, 26, 462–465. doi: 10.1097/PEC.0b013e3181e4f416.CrossRefPubMedGoogle Scholar
  83. Wallendorf, M., & Belk, R. W. (1989). Assessing trustworthiness in naturalistic consumer research. In E. C. Hirschman (Ed.), Interpretive consumer research (pp. 69–84). Provo, UT: Association for Consumer Research.Google Scholar
  84. Westphal, F., Junge, T., Sonnichsen, F., Rosner, P., & Schaper, J. (2010). Ein neuer wirkstoff in SPICE-artigen Kräutermischungen: charakterisierung von JWH-250, seinen methyl-und trimethylsilylderivaten [A new compound in herbal mixtures: characterisation of JWH-250, its methyl- and trimethylsilyl-derivatives]. Toxichem Krimtech, 77, 46–58.Google Scholar
  85. Winstock, A. R., & Barratt, M. J. (2013). Synthetic cannabis: A comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug and Alcohol Dependence, 131, 106–111. doi: 10.1016/j.drugalcdep.2012.12.011.CrossRefPubMedGoogle Scholar
  86. Zimmermann, U. S., Winkelmann, P. R., Pilhatsch, M., Nees, J. A., Spanagel, R., & Schulz, K. (2009). Withdrawal phenomena and dependence syndrome after the consumption of “spice gold”. Deutsches Ärzteblatt International, 106, 464–467. doi: 10.3238/arztebl.2009.0464.PubMedPubMedCentralGoogle Scholar
  87. Zuba, D., Byrska, B., & Maciow, M. (2011). Comparison of “herbal highs” composition. Analytical and Bioanalytical Chemistry, 400, 119–126. doi: 10.1007/s00216-011-4743-7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.School of Health SciencesWaterford Institute of TechnologyWaterfordIreland

Personalised recommendations